Zai Lab Future Growth
Future criteria checks 5/6
Zai Lab is forecast to grow earnings and revenue by 68.2% and 34% per annum respectively. EPS is expected to grow by 66.8% per annum. Return on equity is forecast to be -11.5% in 3 years.
Key information
68.2%
Earnings growth rate
66.8%
EPS growth rate
Biotechs earnings growth | 28.4% |
Revenue growth rate | 34.0% |
Future return on equity | -11.5% |
Analyst coverage | Good |
Last updated | 21 Nov 2024 |
Recent future growth updates
Recent updates
The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Nov 15Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Sep 28Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?
Sep 23Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why
Jun 12Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified
May 14A Risky Bet: Zai Lab's Uncertain Future
Apr 16Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Mar 29We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S
Jan 18Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 24We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?
Feb 16Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 926 | 65 | 38 | 123 | 12 |
12/31/2025 | 584 | -172 | -200 | -143 | 15 |
12/31/2024 | 393 | -269 | -319 | -263 | 14 |
9/30/2024 | 356 | -271 | -219 | -174 | N/A |
6/30/2024 | 323 | -298 | -215 | -202 | N/A |
3/31/2024 | 291 | -339 | -223 | -219 | N/A |
12/31/2023 | 267 | -335 | -193 | -198 | N/A |
9/30/2023 | 263 | -301 | -291 | -293 | N/A |
6/30/2023 | 252 | -393 | -371 | -364 | N/A |
3/31/2023 | 231 | -410 | -368 | -350 | N/A |
12/31/2022 | 215 | -443 | -393 | -368 | N/A |
9/30/2022 | 197 | -593 | -438 | -411 | N/A |
6/30/2022 | 182 | -529 | -472 | -446 | N/A |
3/31/2022 | 171 | -554 | -494 | -467 | N/A |
12/31/2021 | 144 | -704 | -568 | -549 | N/A |
9/30/2021 | 115 | -569 | -458 | -441 | N/A |
6/30/2021 | 87 | -537 | -374 | -359 | N/A |
3/31/2021 | 61 | -454 | -357 | -346 | N/A |
12/31/2020 | 49 | -269 | -227 | -216 | N/A |
9/30/2020 | 39 | -239 | -219 | -212 | N/A |
6/30/2020 | 29 | -240 | -212 | -200 | N/A |
3/31/2020 | 19 | -201 | -203 | -189 | N/A |
12/31/2019 | 13 | -195 | -206 | -191 | N/A |
9/30/2019 | 8 | -212 | -209 | -196 | N/A |
6/30/2019 | 4 | -181 | N/A | N/A | N/A |
3/31/2019 | 2 | -160 | N/A | N/A | N/A |
12/31/2018 | 0 | -139 | -108 | -98 | N/A |
9/30/2018 | N/A | -89 | N/A | N/A | N/A |
6/30/2018 | N/A | -67 | N/A | N/A | N/A |
3/31/2018 | N/A | -59 | N/A | N/A | N/A |
12/31/2017 | N/A | -50 | N/A | -32 | N/A |
9/30/2017 | N/A | -50 | N/A | N/A | N/A |
6/30/2017 | N/A | -50 | N/A | -41 | N/A |
3/31/2017 | N/A | -44 | N/A | -37 | N/A |
12/31/2016 | N/A | -38 | N/A | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZLAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: ZLAB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ZLAB is expected to become profitable in the next 3 years.
Revenue vs Market: ZLAB's revenue (34% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: ZLAB's revenue (34% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZLAB is forecast to be unprofitable in 3 years.